Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Diabetic Macular Edema: early-phase trial registry
10 of 64 indexed Diabetic Macular Edema trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #215 of 28,707 conditions by registered trial count.
64 US clinical trials · 10 currently recruiting · #215 of 28,707 conditions by registered trial count
Diabetic Macular Edema: 64 US clinical trials tracked, 10 recruiting.
Diabetic Macular Edema is the subject of 64 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 18 are in Phase 3-4 (later-stage) and 38 in Phase 1-2 (earlier-stage). The most active sponsor is Hoffmann-La Roche, running 5 of these trials.
Enrollment posture brief
Registry condition diabetic-macular-edema
OPEN 10 | RECR 16% | LATE 18 | EARLY 38 | RANK #215 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Bacterial Infections (16% recruiting · 19 trials)
Diabetic Macular Edema lists 10 open slots (16% of 64 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Diabetic Macular Edema on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Diabetic Macular Edema is recruiting below its size-band peers.
10 of 64 indexed trials (15.6%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Diabetic Macular Edema trials is spread across many organizations.
Hoffmann-La Roche accounts for 5 of 64 trials (7.8%). 47 distinct sponsors appear on at least one study for this condition label.
-
Typical Diabetic Macular Edema enrolment sits around 93 participants.
Median target enrolment is 93 among the 64 trials that report a genuine target (sentinel values excluded). 33 of those (51.6%) plan for fewer than 100 participants.
-
Diabetic Macular Edema research is mostly interventional.
58 interventional and 6 observational studies make up this index (90.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
64 total, page 1 of 2
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
Hoffmann-La Roche
NCT04108156
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
Genentech
NCT06850922
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
EyePoint Pharmaceuticals
NCT07449923
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
EyePoint Pharmaceuticals
NCT07449936
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
Genentech
NCT07425522
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
Eclipse Life Sciences
NCT06536491
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
Ocugen
NCT05802329
Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)
Sierra Eye Associates
NCT06942520
Kamuvudine-9 (K9) in Diabetic Macular Edema
Dr. Bryan Strelow
NCT07458061
Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)
Michelle Abou-Jaoude
NCT06781255
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
Hoffmann-La Roche
NCT05476926
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Regeneron Pharmaceuticals
NCT06491914
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)
Oculis
NCT05066997
Treat & Extend Versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: a Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial
McMaster University
NCT05610319
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)
Oculis
NCT06172257
A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)
Alimera Sciences
NCT04469595
Predicting Diabetic Retinopathy From Risk Factor Data and Digital Retinal Images
Charles Drew University of Medicine and Science
NCT03694145
A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema
Genentech
NCT05224102
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)
Genentech
NCT06847854
Evaluation of Tonabersat for DME
Jaeb Center for Health Research
NCT05727891
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
Outlook Therapeutics
NCT05112861
4D-150 in Patients With Diabetic Macular Edema
4D Molecular Therapeutics
NCT05930561
Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME
Ashvattha Therapeutics
NCT05387837
Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)
Adverum Biotechnologies
NCT05607810
Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)
AiViva BioPharma
NCT05698329
Describing Patient With DME, Their Patient Journey and Disease Progression
Boehringer Ingelheim
NCT05966753
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema
Hoffmann-La Roche
NCT04432831
Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool
Eyenuk
NCT03112005
Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
Novartis Pharmaceuticals
NCT03481634
Anti-VEGF Treatment for Prevention of PDR/DME
Jaeb Center for Health Research
NCT02634333
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
Regeneron Pharmaceuticals
NCT02712008
NOTAL-OCT V.2.5 vs Commercial OCT in AMD Patients
Notal Vision
NCT03969303
Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy
Fovea Pharmaceuticals
NCT01319487
PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
Quark Pharmaceuticals
NCT01445899
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
Outlook Therapeutics
NCT04516278
A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema
Hoffmann-La Roche
NCT05151744
A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema
Opthea Limited
NCT03397264
A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema
Palmetto Retina Center
NCT01934556
A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema
Oxurion
NCT04527107
Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)
KalVista Pharmaceuticals
NCT03466099
NSAID Phase II for Non-central Involved Diabetic Macular Edema (DME)
Jaeb Center for Health Research
NCT01331005
First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers
Curacle Co.
NCT04795037
30g vs 33g Needle for Intravitreal Injections
Wills Eye
NCT03038048
Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema
Rocky Mountain Retina Consultants
NCT00387582
Safety and Exploratory Efficacy Study of SF0166 for the Treatment of Diabetic Macular Edema (DME)
OcuTerra Therapeutics
NCT02914613
Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab
California Retina Consultants
NCT02107131
Cooling Anesthesia for Intravitreal Injection
Recens Medical
NCT03732287
Topical Proparacaine Eye Drops to Improve the Experience of Patients Undergoing Intravitreal Injections
Mayo Clinic
NCT02951351
A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe
Hoffmann-La Roche
NCT05569148
Safety and Tolerability Study of the Helical Intravitreal Triamcinolone Implant in Diabetic Macular Edema
SurModics
NCT00915837
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 23 |
| Phase 2 | 15 |
| Phase 3 | 11 |
| Phase 4 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Diabetic Macular Edema records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Diabetic Macular Edema trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Diabetic Macular Edema page
64 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 Diabetic Macular Edema trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Hoffmann-La Roche sponsors the most Diabetic Macular Edema trials on record, review their full trial history before evaluating a specific study. See Hoffmann-La Roche's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diabetic Macular Edema condition card totals 64 registered trials; most-linked intervention Faricimab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.